Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год
Применить Всего найдено 14. Отображено 14.
21-01-2021 дата публикации

Antibodies Binding to Vista at Acidic pH

Номер: US20210017283A1
Автор: Bahjat Keith Sadoon, Borges Luis, Chen Guodong, Critton David A., Deng Xiaodi, Deyanova Ekaterina G., Huang Richard Y., Johnston Robert J., Korman Alan J., Pinckney Jason R., RAJPAL ARVIND, Rakestraw Ginger, Rankin Andrew, Sheppard Paul O., Su Lin Hui
Принадлежит:

The present application relates to antibodies specifically binding to the V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) at acidic pH and their use in cancer treatment. In some embodiments, the antibodies bind specifically to human VISTA at acidic pH, but do not significantly bind to human VISTA at neutral or physiological pH. 1. An isolated antibody that binds specifically to human VISTA (hVISTA) in acidic conditions.2. The isolated antibody of claim 1 , which binds specifically to hVISTA in acidic conditions claim 1 , but not significantly in neutral or physiological conditions.3. The isolated antibody of or claim 1 , wherein the antibody binds to hVISTA in acidic conditions with a Kthat is at least 10 fold lower than its Kin neutral or physiological conditions.4. The isolated antibody of any one of to claim 1 , wherein the antibody binds to hVISTA in acidic conditions with a Kthat is at least 100 fold lower than its Kin neutral or physiological conditions.5. The isolated antibody of any one of - claim 1 , wherein the antibody binds to hVISTA in acidic conditions with a Kthat is at least 1000 fold lower than its Kin neutral or physiological conditions.6. The isolated antibody of any one of - claim 1 , wherein the antibody binds to hVISTA in neutral or physiological conditions with a Kof 10M or more.7. The isolated antibody of any one of - claim 1 , wherein the antibody binds to hVISTA in neutral or physiological conditions with a Kof 10M or more.8. The isolated antibody of any one of - claim 1 , wherein the antibody binds to hVISTA in neutral or physiological conditions with a Kof 10M or more.9. The isolated antibody of any one of - claim 1 , wherein the antibody binds to hVISTA in acidic conditions with a Kof 10M or less.10. The isolated antibody of any one of - claim 1 , wherein the antibody binds to hVISTA in acidic conditions with a Kof 10M or less.11. The isolated antibody of any one of - claim 1 , wherein the antibody binds to ...

Подробнее
Номер записи: 1
10-03-2022 дата публикации

Antibodies Binding to Vista at Acidic pH

Номер: US20220073617A1
Автор: Bahjat Keith Sadoon, Borges Luis, Chen Guodong, Critton David A., Deng Xiaodi, Deyanova Ekaterina G., Huang Richard Y., Johnston Robert J., Korman Alan J., LEMAR Hadia, NAYEEM Akbar, Pinckney Jason R., Quigley Michael, RAJPAL ARVIND, Rakestraw Ginger, Rankin Andrew, Sheppard Paul O., Su Lin Hui
Принадлежит:

The present application relates to antibodies specifically binding to the V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) at acidic pH and their use in cancer treatment. In some embodiments, the antibodies bind specifically to human VISTA at acidic pH, but do not significantly bind to human VISTA at neutral or physiological pH. 1171.-. (canceled)172. An isolated antibody that binds specifically to human VISTA (hVISTA) , wherein the antibody comprises a heavy chain variable region (VH) and a light chain variable region (VL) , wherein the VH and VL comprise complementarity determining regions (CDRs) of P1-070976 (SEQ ID Nos: 509-511 and 500-502 , respectively) , P1-070976_H95D (SEQ ID Nos: 512-514 and 500-502 , respectively) , VISTA.4 (SEQ ID Nos: 503-505 and 500-502 , respectively) , P1-065333 (SEQ ID Nos: 506-508 and 500-502 , respectively) , or P1-070976_E97P (SEQ ID Nos: 515-517 and 500-502 , respectively).173. The isolated antibody of claim 172 , wherein the VH comprises an amino acid sequence that is at least 90% identical to the VH of P1-070976 (SEQ ID NO: 474) claim 172 , P1-070976_H95D (SEQ ID NO: 477) claim 172 , VISTA.4 (SEQ ID NO: 492) claim 172 , P1-065333 (SEQ ID NO: 473) claim 172 , or P1-070976_E97P (SEQ ID NO: 478); and/orwherein the VL comprises an amino acid sequence that is at least 90% identical to the VL of P1-070976, P1-070976_H95D, VISTA.4, P1-065333, or P1-070976_E97P (corresponding to SEQ ID NO: 493 or SEQ ID NO: 479).174. The isolated antibody of claim 172 , wherein the VH comprises an amino acid sequence that is at least 95% identical to the VH of P1-070976 (SEQ ID NO: 474) claim 172 , P1-070976_H95D (SEQ ID NO: 477) claim 172 , VISTA.4 (SEQ ID NO: 492) claim 172 , P1-065333 (SEQ ID NO: 473) claim 172 , or P1-070976_E97P (SEQ ID NO: 478); and/orwherein the VL comprises an amino acid sequence that is at least 95% identical to the VL of P1-070976, P1-070976_H95D, VISTA.4, P1-065333, or P1-070976_E97P (corresponding ...

Подробнее
Номер записи: 2
12-03-2020 дата публикации

Antibodies Binding to ILT4

Номер: US20200079848A1
Автор: Bee Christine, Chen Diana Yuhui, Chen Guodong, Deng Xiaodi, Deyanova Ekaterina G., HAN Michelle Minhua, Huang Richard Y., Korman Alan J., Liang Linda, Lonberg Nils, Rankin Andrew, SCHEBYE Xiao Min, Selby Mark J., TOTH Joseph, TRUONG Hong-An
Принадлежит:

The present application relates to antibodies specifically binding to immunoglobulin-like transcript 4 (ILT4), which is also known as LILRB2, LIR2, MIR10, and CD85d, and corresponding nucleic acids, host cells, compositions, and uses. In some embodiments, the antibodies bind specifically to human ILT4, but do not significantly bind to ILT2, ILT3, or ILT5, or to other members of the LILRA or LILRB families. 1. (canceled)2. (canceled)3. (canceled)4. (canceled)5. The isolated antibody of that specifically binds to human ILT4 (hILT4 or ILT4) , which comprises(a) a VH comprising the amino acid sequence of the VH CDR1, CDR2 and CDR3 of 9G4 (SEQ ID Nos: 125-127) and a VL comprising the amino acid sequence of the VL CDR1, CDR2 and CDR3 of 9G4 (SEQ ID Nos: 128-130);(b) a VH comprising the amino acid sequence of the VH CDR1, CDR2 and CDR3 of 9C8 (SEQ ID Nos: 131-133) and a VL comprising the amino acid sequence of the VL CDR1, CDR2 and CDR3 of 9C8 (SEQ ID Nos: 134-136);(c) a VH comprising the amino acid sequence of the VH CDR1, CDR2 and CDR3 of 2H2 (SEQ ID Nos: 137-139) and a VL comprising the VL CDR1, CDR2 and CDR3 of 2H2 (SEQ ID Nos: 140-142);(d) a VH comprising the amino acid sequence of the VH CDR1, CDR2 and CDR3 of 2E5 (SEQ ID Nos: 143-145) and a VL comprising the amino acid sequence of the VL CDR1, CDR2 and CDR3 of 2E5 (SEQ ID Nos: 146-148);(e) a VH comprising the amino acid sequence of the VH CDR1, CDR2 and CDR3 of 24E5 (SEQ ID Nos: 149-151) and a VL comprising the amino acid sequence of the VL CDR1, CDR2 and CDR3 of 24E5 (SEQ ID Nos: 152-154);(f) a VH comprising the amino acid sequence of the VH CDR1, CDR2 and CDR3 of 21D9 (SEQ ID Nos: 155-157) and a VL comprising the amino acid sequence of the VL CDR1, CDR2 and CDR3 of 21D9 (SEQ ID Nos: 158-160);(g) a VH comprising the amino acid sequence of the VH CDR1, CDR2 and CDR3 of 21D9.b (SEQ ID Nos: 155-157) and a VL comprising the amino acid sequence of the VL CDR1, CDR2 and CDR3 of 21D9.b (SEQ ID Nos: 158-160);(h) a VH ...

Подробнее
Номер записи: 3
27-05-2021 дата публикации

ANTI-CD27 ANTIBODIES AND USES THEREOF

Номер: US20210155703A1
Автор: Chen Guodong, DESHPANDE Shrikant, Deyanova Ekaterina G., Huang Haichun, Huang Richard Y., Korman Alan J., Lu Li-Sheng, Selby Mark J., SRINIVASAN Mohan, ZHANG JUN
Принадлежит:

This disclosure provides isolated antibodies that bind specifically to CD27 with high affinity. The disclosure provides methods for treating a subject afflicted with a cancer comprising administering to the subject a therapeutically effective amount of an anti-CD27 antibody as monotherapy or in combination with a checkpoint inhibitor, such as an anti-PD-1, anti-PD-L1, or anti-CTLA-4 antibody. 1. A monoclonal antibody or an antigen-binding portion thereof that specifically binds to human CD27 and does not block binding of its CD70 ligand as measured by surface plasmon resonance (SPR) or flow cytometry , wherein the antibody or fragment thereof:{'sub': 'D', '(a) binds to human CD27 with a Kof about 100 nM or lower, about 90 nM or lower, about 80 nM or lower, about 70 nM or lower, about 60 nM or lower, about 50 nM or lower, about 40 nM or lower, between about 1 nM and about 100 nM, between about 10 nM and about 70 nM, between about 10 nM and about 50 nM, or between about 40 nM and about 45 nM, and/or'}{'sub': '50', '(b) induces NF-κB and MAPK signaling with an ECof about 0.5 nM or lower, about 0.4 nM or lower, about 0.3 nM or lower, between about 0.005 nM and about 0.5 nM, between about 0.01 nM and about 0.4 nM, or between about 0.02 nM and about 0.25 nM in naïve human T cells stimulated by an anti-CD3 antibody and an anti-CD28 antibody.'}2. A monoclonal antibody or an antigen-binding portion thereof that specifically binds to an epitope located within discontinuous regions spanning approximately amino acid residues 21-41 and 52-57 of human CD27 , a sequence of which is set forth as SEQ ID NO: 1 , as determined by hydrogen-deuterium exchange mass spectrometry (HDX-MS) and/or fast photochemical oxidation of proteins (FPOP) epitope mapping.3. A monoclonal antibody or an antigen-binding portion thereof that specifically binds to human CD27 , which:{'sub': 'H', '(a) comprises a heavy chain variable region (V) comprising a CDR1 comprising consecutively linked amino acids ...

Подробнее
Номер записи: 4
26-09-2019 дата публикации

ANTIBODIES BINDING TO VISTA AT ACIDIC pH

Номер: WO2019183040A1
Автор: Alan Korman, Andrew Rankin, Andy X. DENG, Arvind Rajpal, David CRITTON, Ekaterina G. DEYANOVA, Ginger RAKESTRAW, Guodong Chen, Jason PINCKNEY, Keith Sadoon Bahjat, Linhui Julie SU, Luis Borges, Paul O. Sheppard, Richard Y. HUANG, Robert J. Johnston
Принадлежит: BRISTOL-MYERS SQUIBB COMPANY, FIVE PRIME THERAPEUTICS, INC.

The present application relates to antibodies specifically binding to the V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) at acidic pH and their use in cancer treatment. In some embodiments, the antibodies bind specifically to human VISTA at acidic pH, but do not significantly bind to human VISTA at neutral or physiological pH.

Подробнее
Номер записи: 5
16-01-2020 дата публикации

Antibodies binding to ilt4

Номер: WO2020014132A2
Автор: Alan J. Korman, Andrew Rankin, Christine BEE, Diana Yuhui CHEN, Ekaterina G. DEYANOVA, Guodong Chen, Hong-An TRUONG, Joseph Toth, Linda Liang, Mark J. Selby, Michelle Minhua HAN, Nils Lonberg, Richard Y. HUANG, Xiao Min Schebye, Xiaodi DENG
Принадлежит: BRISTOL-MYERS SQUIBB COMPANY, FIVE PRIME THERAPEUTICS, INC.

The present application relates to antibodies specifically binding to immunoglobulin-like transcript 4 (ILT4), which is also known as LILRB2, LIR2, MIR10, and CD85d, and corresponding nucleic acids, host cells, compositions, and uses. In some embodiments, the antibodies bind specifically to human ILT4, but do not significantly bind to ILT2, ILT3, or ILT5, or to other members of the LILRA or LILRB families.

Подробнее
Номер записи: 6
16-01-2020 дата публикации

Antibodies binding to vista at acidic ph

Номер: WO2020014327A2
Автор: Akbar Nayeem, Alan J. Korman, Andrew Rankin, Arvind Rajpal, David A. CRITTON, Ekaterina G. DEYANOVA, Ginger RAKESTRAW, Guodong Chen, Hadia Lemar, Jason R. PINCKNEY, Keith Sadoon Bahjat, Lin Hui Su, Luis Borges, Michael Quigley, Paul O. Sheppard, Richard Y. HUANG, Robert J. Johnston, Xiaodi DENG
Принадлежит: BRISTOL-MYERS SQUIBB COMPANY, FIVE PRIME THERAPEUTICS, INC.

The present application relates to antibodies specifically binding to the V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) at acidic pH and their use in cancer treatment. In some embodiments, the antibodies bind specifically to human VISTA at acidic pH, but do not significantly bind to human VISTA at neutral or physiological pH.

Подробнее
Номер записи: 7
27-01-2021 дата публикации

Antibodies binding to vista at acidic ph

Номер: EP3768716A1
Автор: Alan J. Korman, Andrew Rankin, Arvind Rajpal, David A. CRITTON, Ekaterina G. DEYANOVA, Ginger RAKESTRAW, Guodong Chen, Jason R. PINCKNEY, Keith Sadoon Bahjat, Lin Hui Su, Luis Borges, Paul O. Sheppard, Richard Y. HUANG, Robert J. Johnston, Xiaodi DENG
Принадлежит: Bristol Myers Squibb Co, Five Prime Therapeutics Inc

The present application relates to antibodies specifically binding to the V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) at acidic pH and their use in cancer treatment. In some embodiments, the antibodies bind specifically to human VISTA at acidic pH, but do not significantly bind to human VISTA at neutral or physiological pH.

Подробнее
Номер записи: 8
16-01-2020 дата публикации

Antibodies binding to ilt4

Номер: CA3104530A1
Автор: Alan J. Korman, Andrew Rankin, Christine BEE, Diana Yuhui CHEN, Ekaterina G. DEYANOVA, Guodong Chen, Hong-An TRUONG, Joseph Toth, Linda Liang, Mark J. Selby, Michelle Minhua HAN, Nils Lonberg, Richard Y. HUANG, Xiao Min Schebye, Xiaodi DENG
Принадлежит: Bristol Myers Squibb Co, Five Prime Therapeutics Inc

The present application relates to antibodies specifically binding to immunoglobulin-like transcript 4 (ILT4), which is also known as LILRB2, LIR2, MIR10, and CD85d, and corresponding nucleic acids, host cells, compositions, and uses. In some embodiments, the antibodies bind specifically to human ILT4, but do not significantly bind to ILT2, ILT3, or ILT5, or to other members of the LILRA or LILRB families.

Подробнее
Номер записи: 9
24-05-2021 дата публикации

Sight-binding antibodies to acidic pH

Номер: CL2021000012A1
Автор: A Critton David, Borges Luis, Chen Guodong, Deng Xiaodi, G Deyanova Ekaterina, hui su Lin, J Johnston Robert, J Korman Alan, LEMAR Hadia, NAYEEM Akbar, O Sheppard Paul, Quigley Michael, R Pinckney Jason, RAJPAL ARVIND, Rakestraw Ginger, Rankin Andrew, Sadoon Bahjat Keith, Y Huang Richard
Принадлежит: Bristol Myers Squibb Co, Five Prime Therapeutics Inc

La presente solicitud se relaciona con anticuerpos que se unen específicamente al supresor de activación de linfocitos T que contiene inmunoglobulina con dominio V (VISTA) a pH ácido y su uso en el tratamiento del cáncer. En algunas modalidades, los anticuerpos se unen específicamente a VISTA humano a pH ácido, pero no se unen significativamente a VISTA humano a pH neutro o fisiológico. The present application relates to antibodies that specifically bind to the T-lymphocyte activation suppressor containing V domain immunoglobulin (VISTA) at acidic pH and their use in the treatment of cancer. In some embodiments, the antibodies specifically bind to human VISTA at acidic pH, but do not bind significantly to human VISTA at neutral or physiological pH.

Подробнее
Номер записи: 10
09-03-2021 дата публикации

Antibodies binding to ilt4.

Номер: MX2021000009A
Автор: Alan J Korman, Andrew Rankin, Christine BEE, Diana Yuhui CHEN, Ekaterina G Deyanova, Guodong Chen, Hong-An TRUONG, Joseph Toth, Linda Liang, Mark J Selby, Michelle Minhua HAN, Nils Lonberg, Richard Y Huang, Xiao Min Schebye, Xiaodi DENG
Принадлежит: Five Prime Therapeutics Inc

La presente solicitud se refiere a anticuerpos que se unen específicamente a la transcripción de tipo inmunoglobulina 4 (ILT4), que también se denomina LILRB2, LIR2, MIR10 y CD85d, y ácidos nucleicos, células hospedadoras, composiciones y usos correspondientes. En algunas modalidades, los anticuerpos se unen específicamente a ILT4 humana, pero no se unen de manera significativa a ILT2, ILT3, o ILT5, o a otros miembros de las familias LILRA o LILRB.

Подробнее
Номер записи: 11
26-05-2023 дата публикации

ilt4-binding antibodies

Номер: CL2022002868A1
Автор: Bee Christine, Chen Guodong, Deng Xiaodi, G Deyanova Ekaterina, J Korman Alan, J Selby Mark, Liang Linda, Lonberg Nils, Min Schebye Xiao, Minhua Han Michelle, Rankin Andrew, TOTH Joseph, TRUONG Hong-An, Y Huang Richard, Yuhui Chen Diana
Принадлежит: Bristol Myers Squibb Co, Five Prime Therapeutics Inc

La presente solicitud se refiere a anticuerpos que se unen específicamente a la transcripción de tipo inmunoglobulina 4 (ILT4), que también se denomina LILRB2, LIR2, MIR10 y CD85d, y ácidos nucleicos, células hospedadoras, composiciones y usos correspondientes. En algunas realizaciones, los anticuerpos se unen específicamente a ILT4 humana, pero no se unen de manera significativa a ILT2, ILT3, o ILT5, o a otros miembros de las familias LILRA o LILRB.

Подробнее
Номер записи: 12
19-01-2024 дата публикации

Anticuerpos de unión a vista a ph ácido

Номер: CL2023002543A1
Автор: A Critton David, Borges Luis, Chen Guodong, Deng Xiaodi, G Deyanova Ekaterina, hui su Lin, J Johnston Robert, J Korman Alan, LEMAR Hadia, NAYEEM Akbar, O Sheppard Paul, Quigley Michael, R Pinckney Jason, RAJPAL ARVIND, Rakestraw Ginger, Rankin Andrew, Sadoon Bahjat Keith, Y Huang Richard
Принадлежит: Bristol Myers Squibb Co, Five Prime Therapeutics Inc

La presente solicitud se relaciona con anticuerpos que se unen específicamente al supresor de activación de linfocitos T que contiene inmunoglobulina con dominio V (VISTA) a pH ácido y su uso en el tratamiento del cáncer. En algunas modalidades, los anticuerpos se unen específicamente a VISTA humano a pH ácido, pero no se unen significativamente a VISTA humano a pH neutro o fisiológico.

Подробнее
Номер записи: 13
17-09-2024 дата публикации

Antibodies binding to vista at acidic pH

Номер: US12091462B2
Автор: Akbar Nayeem, Alan J. Korman, Andrew Rankin, Arvind Rajpal, David A. CRITTON, Ekaterina G. DEYANOVA, Ginger RAKESTRAW, Guodong Chen, Hadia Lemar, Jason R. PINCKNEY, Keith Sadoon Bahjat, Lin Hui Su, Luis Borges, Michael Quigley, Paul O. Sheppard, Richard Y. HUANG, Robert J. Johnston, Xiaodi DENG
Принадлежит: Bristol Myers Squibb Co, Five Prime Therapeutics Inc

The present application relates to antibodies specifically binding to the V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) at acidic pH and their use in cancer treatment. In some embodiments, the antibodies bind specifically to human VISTA at acidic pH, but do not significantly bind to human VISTA at neutral or physiological pH.

Подробнее
Номер записи: 14